prikaz prve stranice dokumenta Methodology for clinical genotyping of CYP2D6 and CYP2C19
  Download
PDF 1.18 MB
Scientific paper - Original scientific paper
Methodology for clinical genotyping of CYP2D6 and CYP2C19
Translational Psychiatry, 11 (2021), 1; 596. https://doi.org/10.1038/s41398-021-01717-9
Carvalho Henriques, Beatriz; Buchner, Avery; Hu, Xiuying; Wang, Yabing; Yavorskyy, Vasyl; Wallace, Keanna; Dong, Rachael; Martens, Kristina; Carr, Michael S.; Behroozi Asl, Bahareh; Hague, Joshua; Sivapalan, Sudhakar; Maier, Wolfgang; Dernovsek, Mojca Z.; Henigsberg, Neven; Hauser, Joanna; Souery, Daniel; Cattaneo, Annamaria; Mors, Ole; Rietschel, Marcella; Pfeffer, Gerald; Hume, Stacey; Aitchison, Katherine J. More authors...

Cite this document

Carvalho Henriques, B., Buchner, A., Hu, X., Wang, Y., Yavorskyy, V., Wallace, K. ... Aitchison, K. J. (2021). Methodology for clinical genotyping of CYP2D6 and CYP2C19. Translational Psychiatry, 11. (1). doi: 10.1038/s41398-021-01717-9

Carvalho Henriques, Beatriz, et al. "Methodology for clinical genotyping of CYP2D6 and CYP2C19." Translational Psychiatry, vol. 11, no. 1, 2021. https://doi.org/10.1038/s41398-021-01717-9

Carvalho Henriques, Beatriz, Avery Buchner, Xiuying Hu, Yabing Wang, Vasyl Yavorskyy, Keanna Wallace, Rachael Dong, et al. "Methodology for clinical genotyping of CYP2D6 and CYP2C19." Translational Psychiatry 11, no. 1 (2021). https://doi.org/10.1038/s41398-021-01717-9

Carvalho Henriques, B., et al. (2021) 'Methodology for clinical genotyping of CYP2D6 and CYP2C19', Translational Psychiatry, 11(1). doi: 10.1038/s41398-021-01717-9

Carvalho Henriques B, Buchner A, Hu X, Wang Y, Yavorskyy V, Wallace K, and sur.. Methodology for clinical genotyping of CYP2D6 and CYP2C19. Translational Psychiatry [Internet]. 2021 November 22 [cited 2024 April 25];11(1). doi: 10.1038/s41398-021-01717-9

B. Carvalho Henriques, et al., "Methodology for clinical genotyping of CYP2D6 and CYP2C19", Translational Psychiatry, vol. 11, no. 1, November 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:591830. [Accessed: 25 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Methodology for clinical genotyping of CYP2D6 and CYP2C19
AuthorBeatriz Carvalho Henriques
AuthorAvery Buchner
AuthorXiuying Hu
AuthorYabing Wang
AuthorVasyl Yavorskyy
AuthorKeanna Wallace
AuthorRachael Dong
AuthorKristina Martens
AuthorMichael S. Carr
AuthorBahareh Behroozi Asl
AuthorJoshua Hague
AuthorSudhakar Sivapalan
AuthorWolfgang Maier
AuthorMojca Z. Dernovsek
AuthorNeven Henigsberg
AuthorJoanna Hauser
AuthorDaniel Souery
AuthorAnnamaria Cattaneo
AuthorOle Mors
AuthorMarcella Rietschel
AuthorGerald Pfeffer
AuthorStacey Hume
AuthorKatherine J. Aitchison
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Psychiatry and Psychological Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Psychiatry
Abstract (english)
Many antidepressants, atomoxetine, and several antipsychotics are metabolized by the cytochrome P450 enzymes CYP2D6 and CYP2C19, and guidelines for prescribers based on genetic variants exist. Although some laboratories offer such testing, there is no consensus regarding validated methodology for clinical genotyping of CYP2D6 and CYP2C19. The aim of this paper was to cross-validate multiple technologies for genotyping CYP2D6 and CYP2C19 against each other, and to contribute to feasibility for clinical implementation by providing an enhanced range of assay options, customizable automated translation of data into haplotypes, and a workflow algorithm. AmpliChip CYP450 and some TaqMan single nucleotide variant (SNV) and copy number variant (CNV) data in the Genome-based therapeutic drugs for depression (GENDEP) study were used to select 95 samples (out of 853) to represent as broad a range of CYP2D6 and CYP2C19 genotypes as possible. These 95 included a larger range of CYP2D6 hybrid configurations than have previously been reported using inter-technology data. Genotyping techniques employed were: further TaqMan CNV and SNV assays, xTAGv3 Luminex CYP2D6 and CYP2C19, PharmacoScan, the Ion AmpliSeq Pharmacogenomics Panel, and, for samples with CYP2D6 hybrid configurations, long-range polymerase chain reactions (L-PCRs) with Sanger sequencing and Luminex. Agena MassARRAY was also used for CYP2C19. This study has led to the development of a broader range of TaqMan SNV assays, haplotype phasing methodology with TaqMan adaptable for other technologies, a multiplex genotyping method for efficient identification of some hybrid haplotypes, a customizable automated translation of SNV and CNV data into haplotypes, and a clinical workflow algorithm.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleTranslational Psychiatry
Numberingvol. 11, no. 1, 596
e-ISSN2158-3188
DOIhttps://doi.org/10.1038/s41398-021-01717-9
URN:NBNurn:nbn:hr:105:591830
Publication2021-11-22
Document URLhttps://www.nature.com/articles/s41398-021-01717-9
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-03-09 09:44:55